Can Doximity's Physician Platform Still Command a Premium When the Billing Data Tells Another Story?

Doximity, Inc. (DOCS) reports fiscal fourth quarter 2026 earnings after market close on May 13, 2026, with Wall Street bracing for a sharp deceleration in profitability. The digital healthcare platform faces a critical test: can it sustain the momentum from its AI-powered product rollout while navigating a dramatic year-over-year earnings decline? With the stock trading well below its 200-day moving average and technical signals flashing caution, investors will scrutinize whether management's optimism around AI engagement translates into financial results that can reverse the recent downtrend.

Part 1: Earnings Preview

Doximity operates the leading digital platform for U.S. medical professionals, serving over 85% of U.S. physicians with tools for collaboration, clinical reference, virtual patient visits, and AI-powered search capabilities. The company monetizes its verified network of more than 2 million healthcare professionals through subscription products sold to pharmaceutical, medical device, and healthcare organizations.

Doximity is scheduled to report fiscal Q4 2026 results after the close on May 13, 2026. The consensus estimate calls for $0.17 per share, with estimates ranging from $0.13 to $0.19 across 6 analysts. The most recently reported quarter (Q3 fiscal 2026, ending December 31, 2025) delivered $0.33 per share, beating the $0.32 estimate by 3.13%. However, the year-over-year comparison reveals a stark challenge: the $0.17 consensus represents a 46.88% decline from the $0.32 reported in the same quarter last year (Q4 fiscal 2025).

Three key themes define this earnings story:

AI Product Adoption and Engagement: Management's February commentary highlighted record engagement metrics, with over 1 million quarterly active prescribers on the newsfeed, 720,000 on workflow products, and more than 300,000 using nascent AI features. The critical question is whether this engagement surge translates into revenue acceleration and justifies the company's assertion that "the addition of AI features across our platform has made us more useful than ever." Investors will scrutinize whether AI-driven utility can offset the dramatic earnings decline and support the company's long-term growth trajectory.

Profitability Compression and Margin Dynamics: The sharp year-over-year EPS decline comes despite Doximity's historically strong profitability profile. In Q3, the company posted a 33% net income margin and 60% adjusted EBITDA margin, but net income fell to $61.6 million from $75.2 million year-over-year despite 10% revenue growth. The disconnect between revenue growth and earnings compression—driven by elevated stock-based compensation expense that jumped to $33.5 million from $19.4 million—raises questions about whether the company can maintain its reputation as a high-margin business while investing in AI capabilities.

Revenue Growth Sustainability: Doximity guided fiscal Q4 revenue to $143-144 million, representing modest 4-5% year-over-year growth compared to the 10% growth delivered in Q3. With full-year fiscal 2026 revenue guidance of $642.5-643.5 million (up 12.8% year-over-year), investors will assess whether the company's core subscription business remains resilient amid macroeconomic uncertainty and whether new AI products can drive reacceleration in fiscal 2027.

Analysts remain cautiously optimistic despite the near-term earnings headwinds. The consensus maintains a Buy-equivalent rating with a mean price target of $37.18, implying 41% upside from current levels. However, recent estimate revisions tell a more sobering story: the Q4 consensus has been slashed from $0.32 to $0.17 over the past 90 days, while next quarter's estimate dropped from $0.38 to $0.23. This downward revision cycle reflects growing concern that elevated expenses and moderating growth may persist longer than initially anticipated.

Part 2: Historical Earnings Performance

Doximity has established a consistent pattern of exceeding Wall Street expectations, beating consensus estimates in all eight of the most recent quarters tracked. The company's beat rate is perfect, though the magnitude of outperformance has varied significantly.

The most dramatic beats occurred in fiscal 2025, when Doximity delivered surprise rates of 60.00% (Q4 2025: $0.32 vs. $0.20 estimate), 38.74% (Q2 2025: reported data shows strong outperformance), and 35.99% (Q4 2025: $0.37 vs. $0.27 estimate based on historical data). These outsized surprises reflected the company's ability to convert its expanding physician network into accelerating revenue and maintain exceptional operating leverage.

However, the trend has moderated considerably in recent quarters. The fiscal 2026 results show more modest beats: 17.86% in Q2 (September 2025: $0.33 vs. $0.28), 12.50% in Q1 (June 2025: $0.27 vs. $0.24), and just 3.13% in the most recent Q3 (December 2025: $0.33 vs. $0.32). This compression in surprise magnitude suggests either that analysts have recalibrated their models to better capture the company's performance, or that Doximity's ability to exceed expectations is diminishing as the business matures and faces tougher year-over-year comparisons. The upcoming Q4 report will test whether the company can continue its unbroken streak of beats despite the most challenging setup yet—a consensus estimate that implies a 46.88% year-over-year decline.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Doximity typically reports earnings after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price action around Doximity earnings reveals extreme volatility, with an average absolute Day +1 move of 22.60%—nearly double the options market's current 17.03% expected move. The stock has demonstrated a pronounced tendency toward explosive upside reactions following positive surprises, particularly in fiscal 2025 when strong beats triggered Day +1 gains of 35.99% (February 2025), 34.15% (November 2024), and 38.74% (August 2024).

However, fiscal 2026 has brought a sharp reversal in post-earnings behavior. The most recent three reports produced Day +1 declines of 16.78% (February 2026), 13.25% (November 2025), and 10.08% (May 2025), despite the company beating estimates in each instance. This shift suggests investors are now punishing the stock for guidance disappointments, margin compression, or growth deceleration—even when headline EPS numbers exceed expectations. The Day 0 moves have been relatively muted (averaging just 1.75%), indicating most price action occurs after investors digest the full earnings package including guidance and management commentary. Given the current setup—a dramatically lowered bar, deteriorating technical picture, and recent pattern of post-beat selloffs—investors should prepare for significant volatility in either direction.

Part 2.2: Options Market Expected Move

The options market is pricing a 17.03% expected move through the May 15 expiration, implying a range of $21.95 to $30.96. This sits well below Doximity's 22.60% average absolute Day +1 move over the past eight quarters, suggesting options may be underpricing potential volatility. However, the expected move aligns more closely with the 11.68% average Day +1 range, indicating the market anticipates a more contained reaction than the explosive moves seen in fiscal 2025—perhaps reflecting the lower bar set by reduced estimates and investors' recent tendency to sell rallies.

Part 3: What Analysts Are Saying

Wall Street maintains a Buy-equivalent consensus on Doximity with an average rating of 4.21 out of 5.0, unchanged from one month ago. The analyst community shows 13 Strong Buy ratings, 3 Moderate Buy ratings, and 8 Hold ratings, with no sell recommendations currently active. The mean price target of $37.18 implies 41% upside from the current $26.45 price, with a wide range spanning from a low target of $25.00 to a high of $55.00.

Sentiment has remained unchanged over the past month despite the dramatic downward revision in earnings estimates. This stability masks an underlying shift in the analyst base: one month ago, the consensus included 14 Strong Buys and 1 Strong Sell, compared to today's 13 Strong Buys and 0 Strong Sells. The elimination of the sole bearish voice and addition of two Hold ratings suggests analysts are coalescing around a more neutral near-term view while maintaining conviction in the longer-term story.

The 24-analyst consensus reflects a market grappling with conflicting signals. Bulls point to Doximity's dominant market position (85% of U.S. physicians), expanding AI product suite driving record engagement, and historically strong profitability as reasons the stock deserves a premium valuation. The 41% implied upside to the mean target suggests many analysts view the recent 43% decline from the 200-day moving average as overdone. However, the clustering of 8 Hold ratings and the dramatic 90-day estimate cuts (Q4 EPS down from $0.32 to $0.17, next quarter from $0.38 to $0.23) indicate growing caution about near-term execution and the sustainability of margins amid elevated investment spending.

Part 4: Technical Picture

Doximity enters earnings in a deteriorating technical position, with the Barchart Technical Opinion registering a 40% Sell signal—an improvement from the 56% Sell reading one week ago and the 100% Sell signal one month ago, but still firmly in bearish territory. The recent moderation suggests some stabilization after a severe downtrend, though the overall setup remains cautious.

Timeframe Analysis:

• Short-term (Hold): Neutral signal indicates the immediate trend has stabilized after recent weakness, suggesting neither strong buying nor selling pressure in the near term
• Medium-term (50% Sell): Moderate sell signal reflects ongoing weakness in the intermediate timeframe, indicating the stock remains in a corrective phase
• Long-term (100% Sell): Strong sell signal confirms the longer-term trend has decisively turned negative, with the stock well below key moving averages

Trend Characteristics: The combination of Average strength and Weakest direction indicates the stock is experiencing a well-defined downtrend with limited momentum, suggesting any earnings-driven rally may face resistance from overhead supply.

The moving average structure confirms the bearish technical backdrop. DOCS trades at $26.45, above all short-term averages (5-day: $26.08, 10-day: $25.47, 20-day: $24.84, 50-day: $24.35) but significantly below the critical 100-day ($30.38) and 200-day ($46.34) moving averages. The stock sits 43% below its 200-day average, indicating a severe downtrend that will require a substantial fundamental catalyst to reverse. The positive divergence with short-term averages suggests some recent stabilization, but the wide gap to longer-term averages represents formidable overhead resistance. With the stock attempting to build a base after a prolonged decline, earnings could serve as either a capitulation low if results disappoint further, or a reversal catalyst if management can articulate a credible path back to earnings growth. The technical setup is cautionary but not prohibitive—a strong beat-and-raise scenario could trigger short covering and attract momentum buyers, while any disappointment risks breaking support at the 50-day average and accelerating the downtrend.